What does the recent capacity expansion in Shandong mean for ketoprofen API supply?

What does the recent capacity expansion in Shandong mean for ketoprofen API supply?
Shandong Xin Chenglian Pharma is building a 250-tonne-per-year high-end API project in Zoucheng Chemical Industrial Park, with 20 tonnes allocated to ketoprofen annually. Total investment is 60 million yuan, covering one Class A production workshop, a warehouse, and R&D facilities with 150 pieces of equipment including reactors and distillation units. The project also produces cladribine, avanafil, apixaban, sitagliptin, vildagliptin, and other APIs. This adds to China's already substantial NSAID API capacity. For context, domestic ibuprofen capacity alone exceeds 11,500 tonnes per year versus roughly 1,700 tonnes annual demand, illustrating the oversupply pattern typical of mature analgesic APIs. Ketoprofen's smaller market size means even a 20-tonne addition could influence regional pricing dynamics, especially if multiple similar projects come online simultaneously.